You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 10, 2025

ANTHIM Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: ANTHIM
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for ANTHIM
Recent Clinical Trials for ANTHIM

Identify potential brand extensions & biosimilar entrants

SponsorPhase
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1

See all ANTHIM clinical trials

Pharmacology for ANTHIM
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ANTHIM Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ANTHIM Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ANTHIM Derived from Patent Text Search

These patents were obtained by searching patent claims

Market Dynamics and Financial Trajectory for ANTHIM

Introduction ANTHIM is a biologic drug indicated for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antimicrobial therapy and supportive care[2]. The market dynamics and financial trajectory of ANTHIM are influenced by several factors, including its unique indication, regulatory environment, and competitive landscape.

Regulatory Environment

ANTHIM has been approved by regulatory bodies for its specific use in treating inhalational anthrax. This approval process involves rigorous testing and evaluation to ensure the drug's safety and efficacy[2]. The regulatory environment plays a crucial role in shaping the market dynamics, as it dictates the availability and accessibility of the drug.

Competitive Landscape

The market for biologic drugs is highly competitive, with various drugs vying for market share. However, ANTHIM's unique indication sets it apart from other biologics. The competitive landscape is further influenced by the development of new treatments and the pricing strategies employed by pharmaceutical companies[3].

Financial Trajectory

The financial trajectory of ANTHIM is closely tied to its market performance and sales. While specific financial data for ANTHIM is not readily available, biologic drugs generally command high prices due to their complex production processes and high efficacy rates. The financial metrics for similar biologic drugs can provide insights into the potential revenue streams for ANTHIM[5].

Market Size and Growth

The global market for biologic therapeutic drugs is expected to experience significant growth, driven by the increasing demand for treatments in various therapeutic areas. This growth is projected to continue, with the global market expected to reach $823.4 billion by 2028, at a compound annual growth rate (CAGR) of 12.7%[4].

Pricing Strategies

Pricing strategies play a critical role in the financial trajectory of biologic drugs. Pharmaceutical companies often employ various pricing strategies to maximize revenue while ensuring the drug remains accessible to patients. The pricing dynamics can significantly impact the financial performance of ANTHIM[3].

Clinical Trials and R&D

Ongoing clinical trials and R&D activities are essential for maintaining a competitive edge in the biologic drug market. Continuous innovation and the development of new treatments can enhance the market position and financial performance of ANTHIM[4].

Market Access and Accessibility

Market access and accessibility are critical factors influencing the adoption and sales of biologic drugs. The availability of ANTHIM through various channels, including insurance coverage and patient assistance programs, can impact its market performance and financial trajectory[3].

Conclusion

The market dynamics and financial trajectory of ANTHIM are shaped by its unique indication, regulatory environment, competitive landscape, pricing strategies, ongoing R&D activities, and market access. While specific financial data is not available, the high demand for biologic drugs and the expected growth in the global market suggest a promising financial trajectory for ANTHIM.

Key Takeaways:

  1. Unique Indication: ANTHIM's specific use in treating inhalational anthrax sets it apart from other biologics.
  2. Regulatory Environment: Rigorous testing and approval processes ensure the drug's safety and efficacy.
  3. Competitive Landscape: High competition in the biologic drug market requires continuous innovation.
  4. Financial Metrics: High prices and potential revenue streams are characteristic of biologic drugs.
  5. Market Growth: Expected growth in the global biologic market supports a promising financial trajectory.

FAQs:

  1. What is ANTHIM used for?

    • ANTHIM is indicated for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antimicrobial therapy and supportive care[2].
  2. How does the regulatory environment impact ANTHIM?

    • The regulatory environment dictates the availability and accessibility of ANTHIM through rigorous testing and approval processes[2].
  3. What is the competitive landscape like for biologic drugs?

    • The market for biologic drugs is highly competitive, with various drugs vying for market share. ANTHIM’s unique indication sets it apart from other biologics[3].
  4. How do pricing strategies impact the financial trajectory of biologic drugs?

    • Pricing strategies play a critical role in maximizing revenue while ensuring the drug remains accessible to patients[3].
  5. What are the ongoing R&D activities for biologic drugs?

    • Ongoing clinical trials and R&D activities are essential for maintaining a competitive edge in the biologic drug market[4].

Cited Information:

  1. [1] Cardinal Health. (2023). 2024 Biosimilars Report.
  2. [2] Department of Defense. (2017). Issue No. 1286.
  3. [3] FTC. (2020). Biologics Market Dynamics: Setting the Stage for Biosimilars.
  4. [4] BCC Research. (2023). Biologic Therapeutic Drugs: Technologies and Global Markets.
  5. [5] StockAnalysis. (n.d.). Anthera Pharmaceuticals (ANTH) Financial Ratios and Metrics.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.